Preferred initial strategies in patients with relapsed indolent lymphoma.
| No adverse prognostic features* . | > 1 adverse prognostic features* . | ||
|---|---|---|---|
| Any age . | Age < 55 years No serious co-morbidity . | Age 55-65 years No serious co-morbidity . | Age > 65 years or serious co-morbidity . |
| Standard dose chemotherapy | Allogeneic transplant | Autologous transplant | Monoclonal antibodies |
| Monoclonal antibodies | Autologous transplant | Standard dose chemotherapy | Standard dose chemotherapy |
| Watch and wait | Standard dose chemotherapy | Monoclonal antibodies | |
| Monoclonal antibodies | |||
| No adverse prognostic features* . | > 1 adverse prognostic features* . | ||
|---|---|---|---|
| Any age . | Age < 55 years No serious co-morbidity . | Age 55-65 years No serious co-morbidity . | Age > 65 years or serious co-morbidity . |
| Standard dose chemotherapy | Allogeneic transplant | Autologous transplant | Monoclonal antibodies |
| Monoclonal antibodies | Autologous transplant | Standard dose chemotherapy | Standard dose chemotherapy |
| Watch and wait | Standard dose chemotherapy | Monoclonal antibodies | |
| Monoclonal antibodies | |||
Adverse prognostic features include the presence of constitutional (“B”) symptoms, bulky tumor mass, more than two relapses, LDH > 400 mU/ml (normal = 225 mU/ml), and hemoglobin < 10 g/dL